Gemcitabine and continuous infusion of 5-fluorouracil in locally advanced and metastatic pancreatic cancer: A phase I-II study

Background: Gemcitabine has been recently recognized as standard treatment in advanced pancreatic cancer. To potentiate its single-agent activity we conducted a phase I-II study with the primary objective of establishing the maximum tolererated dose (MTD) of gemcitabine and continuous infusion 5-FU in patients with locally advanced or metastatic pancreatic cancer. Patients and Methods Fifteen patients received a fixed dose of 5-FU 200 mg/mq protracted infusion for six months. Gemcitabine was administered weekly for three out of four weeks for six cycles at escalating doses of 800 mg/mq to 1100 mg/mq. Results: MTD was established at 1000 mg/mq of gemcitabine. Of the 11 evaluable patients, 7 patients had stable disease, 1 had partial response and 3 had progressive disease. Of the 14 patients evaluable at follow-up, median time to progression was 5 months. Median survival was 10 months. Conclusion: This study confirms the good tolerability of the combination, of gemcitabine with 5-FU.